ProAgio induces apoptosis by recruiting caspase 8, that plays an essential role in programmed cell death, to the cytoplasmic area of integrin v3
A protein designed Georgia State Uni researchers can effectively target a cell surface receptor linked to a number of diseases, showing potential as a therapeutic treatment for an array of illnesses, including cancer. ProAgio, which is created from a human protein, targets the cell surface receptor integrin v3 at a novel site that has not been targeted by other scientists. The researchers found ProAgio induces apoptosis of cells that express integrin v3. This integrin has been a focus for drug development because abnormal expression of v3 is linked to the development and progression of a number of diseases.
“This integrin pair, v3, is not expresse...
Read More
Recent Comments